- Home
- PLUT vs SCYX Comparison
PLUT vs SCYX Comparison
Compare PLUT & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUT
- SCYX
- Stock Information
- Founded
- PLUT 2018
- SCYX 1999
- Country
- PLUT Hong Kong
- SCYX United States
- Employees
- PLUT N/A
- SCYX N/A
- Industry
- PLUT
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- PLUT
- SCYX Health Care
- Exchange
- PLUT NYSE
- SCYX Nasdaq
- Market Cap
- PLUT 35.6M
- SCYX 40.9M
- IPO Year
- PLUT 2025
- SCYX 2014
- Fundamental
- Price
- PLUT $2.37
- SCYX $0.94
- Analyst Decision
- PLUT
- SCYX
- Analyst Count
- PLUT 0
- SCYX 0
- Target Price
- PLUT N/A
- SCYX N/A
- AVG Volume (30 Days)
- PLUT 39.5K
- SCYX 82.8K
- Earning Date
- PLUT 01-01-0001
- SCYX 05-20-2025
- Dividend Yield
- PLUT N/A
- SCYX N/A
- EPS Growth
- PLUT N/A
- SCYX N/A
- EPS
- PLUT N/A
- SCYX N/A
- Revenue
- PLUT $1,435,597.00
- SCYX $3,746,000.00
- Revenue This Year
- PLUT N/A
- SCYX $460.12
- Revenue Next Year
- PLUT N/A
- SCYX $253.87
- P/E Ratio
- PLUT N/A
- SCYX N/A
- Revenue Growth
- PLUT 1.42
- SCYX N/A
- 52 Week Low
- PLUT $2.10
- SCYX $0.73
- 52 Week High
- PLUT $4.22
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- PLUT N/A
- SCYX 47.33
- Support Level
- PLUT N/A
- SCYX $0.93
- Resistance Level
- PLUT N/A
- SCYX $1.00
- Average True Range (ATR)
- PLUT 0.00
- SCYX 0.07
- MACD
- PLUT 0.00
- SCYX -0.00
- Stochastic Oscillator
- PLUT 0.00
- SCYX 7.60
About PLUT PLUTUS FINANCIAL GROUP LIMITED
Plutus Financial Group Ltd provides financial services. It mainly offers (i) securities dealings and brokerage services (ii) margin financing services and (iii) underwriting and placing services.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.